Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Also known as ZIO-101-C (Darinaparsin), darinaparsin, S-dimethylarsino-glutathione, Zinapar (TM)
ZIO-101-C · 3 trials · 3 indications
a primary outcome measure is to determine the toxicity profile of oral darinaparsin when given continuously for 21 days followed by a 7 day rest period per cycle
a primary outcome measure is to determine the maximum tolerated dose of oral darinaparsin when given continuously for 21 days followed by a 7 day rest period per cycle
a primary outcome measure is to determine the preliminary activity/efficacy of oral darinaparsin when given continuously for 21 days followed by a 7 day rest period per cycle
a primary outcome measure is to determine the pharmacokinetic profile of oral darinaparsin when given continuously for 21 days followed by a 7 day rest period per cycle
| Arm | Type | Description |
|---|---|---|
| oral darinaparsin | EXPERIMENTAL | open label, single arm, dose escalation |
| Single Arm | EXPERIMENTAL | - |
| Name | Type | Description |
|---|---|---|
| darinaparsin | DRUG | dose escalating, starting at 200 mg twice per day for 21 days continuous followed by a 7 day rest per cycle. |
| ZIO-101-C (Darinaparsin) | DRUG | Dose Escalation study, 200 mg - 900 mg, cumulative daily dose split to be taken BID 7 times a week (\>8 hours between doses) for 3 weeks followed by 1 week of rest |
Inclusion Criteria: * Subjects with histological or cytological confirmation of advanced cancer (solid tumor) that is refractory to standard therapies for their condition; * Men and women of ≥18 years of age; * ECOG performance score ≤2 * Eligible subjects with solid tumors MUST have at least one m...
Top 5 of 9 competitors
| Company | Ticker | Trials | Lead Phase | Drugs |
|---|---|---|---|---|
| AstraZeneca PLC | AZN | 1 | PHASE2 | Durvalumab |
| Nanobiotix SA Sponsored ADR | NBTX | 1 | PHASE1 | NBTXR3 |
| Olema Oncology, Inc. | OLMA | 1 | PHASE1 | OP-3136, Palazestrant |
| Ascentage Pharma Group International Unsponsored ADR | AAPG | 1 | PHASE1 | Olverembatinib |
| Pfizer Inc. | PFE | 1 | N/A | Palbociclib |
ZIO-101-C is an investigational small molecule being studied in advanced cancer, specifically advanced solid tumors and lymphomas. It has been evaluated in Phase 1 clinical trials in adults aged 18 years and older. It is not an approved therapy; the studies were early-stage dose and safety evaluations conducted in Canada and the United States.
ZIO-101-C is being developed by Alaunos Therapeutics, Inc., which trades under the ticker TCRT. The company sponsored the Phase 1 clinical program evaluating oral ZIO-101-C in patients with advanced solid tumors and lymphomas.
ZIO-101-C is in Phase 1 clinical development. Both of its recorded Phase 1 studies in advanced solid tumors and lymphomas have been completed, and no trials are currently active. It is an investigational agent and has not been approved for any indication.
ZIO-101-C has been studied in two completed Phase 1 trials. NCT00592163 evaluated oral ZIO-101-C in advanced solid tumors and lymphomas in Canada with 20 patients. NCT00591422 evaluated oral darinaparsin (ZIO-101-C) in advanced cancer and non-Hodgkin's lymphomas in the United States with 23 patients.
Yes. ZIO-101-C is also known as darinaparsin, and the two names refer to the same investigational small molecule. The Phase 1 trial NCT00591422 is listed under the name oral darinaparsin (ZIO-101-C), confirming that the alternative name identifies the same agent.
The ZIO-101-C clinical program enrolled a total of 23 patients across its studies. The Phase 1 trial NCT00591422 in advanced cancer and non-Hodgkin's lymphomas accounted for 23 participants, while NCT00592163 in advanced solid tumors and lymphomas enrolled 20 patients. Both studies were uncontrolled and non-randomized.